Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 26, 1998

View Archived Issues

Behavioral effects of methylene blue studied in animal models

Safety and efficacy of tazarotene gel demonstrated in psoriasis

Novel antiparkinsonian agent displays improved side effect profile

Celltech: Annual Report 1997

Alferon N Injection for HIV-infected patients makes progress

Aminopterin enters phase II for endometrial cancer

Tripos and Sepracor to collaborate on discovery of HIV protease inhibitors

SSRIs appear safe for use during pregnancy

Animal study indicates efficacy of oral PAF antagonist in allergic rhinitis

Ariflo possesses potent antiinflammatory activity, without GI side effects

T-440: a new antiasthma drug candidate from Tanabe

Mechanism of hypolipidemic effects of monatepil elucidated

PAF antagonist protects against ischemia-reperfusion injury in heart-lung transplantation

Cell adhesion inhibitors from Yoshitomi

Agouron discloses new HIV protease inhibitors

IL-6 suggested to be an endogenous neuroprotective factor

Merck describes newly discovered beta3-adrenoceptor agonists

New mitomycin formulation now under FDA review

First NDA filing for Sonata

Ergo Science establishes Ergoset partnership with J&J units

Strengthened safety labeling for Accutane

Baxter to acquire Somatogen

Xenical scheduled for FDA advisory panel review

Oncologic Drugs Advisory Committee meets next month

Priority review status granted for Avakine

Thyrogen will receive priority review by the FDA; EU application also accepted

Cyclopropane analogues as potent anti-HIV-1 agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...